The vascular adventitia acts as a biological processing center for the retrieval, integration,
storage, and release of key regulators of vessel wall function. It is the most complex …

Dysfunctional bone morphogenetic protein receptor-2 (BMPR2) signaling is implicated in the
pathogenesis of pulmonary arterial hypertension (PAH). We used a transcriptional high …

Rationale: The pathogenesis of pulmonary arterial hypertension (PAH) remains unclear. The
4 microRNAs representing the miR-143 and miR-145 stem loops are genomically clustered …

Background: Pulmonary arterial hypertension (PAH) is characterized by abnormal growth
and enhanced glycolysis of pulmonary artery endothelial cells. However, the mechanisms …

Background—Treatment options for pulmonary arterial hypertension target the prostacyclin,
endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor …

Background Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic
guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate …

At present, six groups of chronic pulmonary hypertension (PH) are described. Among these,
group 1 (and 1′) comprises a group of diverse diseases termed pulmonary arterial …

Pulmonary arterial hypertension (PAH) is a progressive, fatal disease. We studied 674
consecutive adult patients who were prospectively enrolled in the French PAH registry (121 …

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease leading to right
heart failure and ultimately death if untreated. The first classification of PH was proposed in …

Pulmonary arterial hypertension, which is characterized by vascular proliferation and
remodeling of small pulmonary vessels, leads to a progressive increase in pulmonary …